Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+ in patients with grass pollen-induced allergic rhinoconjunctivitis during two successive pollen seasons

Trial Profile

A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+ in patients with grass pollen-induced allergic rhinoconjunctivitis during two successive pollen seasons

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABT 011 (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech
  • Most Recent Events

    • 07 Oct 2019 According to a ASIT biotech media release, results from this study is expected in December 2019.
    • 07 Oct 2019 According to a ASIT biotech media release, based on the the positive outcome of this study, the company expects regulatory filings in 2020.
    • 26 Sep 2019 According to an ASIT biotech media release, the last patient last visit has been completed in this study and the company remains on track to deliver primary efficacy results in December 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top